Consensus Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
29.15 ^CNY	+4.07%		+6.82%	-10.83%

04:00pm	FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC	CI
May. 24	Mabwell Announces 9MW2821 Clinical Data	CI

Evolution of the average Target Price on Mabwell (Shanghai) Bioscience Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

0931dc571ab2e74.rvOaU4jxRD0qZdQga3P-ftZQ-REZhUfYRaNDXSrvDTg.mYbMYs_GLkp7JrJaNCGtT6AysWhdtx2tM8QBMnuBO1v5le8V-YB0TkQhhQ~3f00c7afa114815709575abee7a2f810